AbbVie acquired DJS Antibodies for ~$255M cash plus undisclosed development milestones for DJS-002. DJS's HEPTAD platform targets transmembrane proteins (e.g., GPCRs) that have been historically difficult to drug. Lead program DJS-002 is a preclinical first-in-class LPAR1 antagonist antibody for IPF. The acquisition completed in Q4 2022: DJS Antibodies Ltd is listed as a UK subsidiary in AbbVie's FY2022 Form 10-K (Exhibit 21, as of Dec 31, 2022).